Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Mayo Clinic
STORM Therapeutics LTD
Eli Lilly and Company
Neonc Technologies, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Exscientia AI Limited
Radiopharm Theranostics, Ltd
Ocellaris Pharma, Inc.
Tanabe Pharma America, Inc.
DualityBio Inc.
BicycleTx Limited
Volastra Therapeutics, Inc.
LigaChem Biosciences, Inc.
Incyte Corporation
Yuhan Corporation
NuCana plc
Medicenna Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
Klus Pharma Inc.
Precision Biologics, Inc
Portage Biotech
RAPT Therapeutics, Inc.
Taiho Oncology, Inc.
Cyteir Therapeutics, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Cancer Research UK
NextCure, Inc.
Evopoint Biosciences Inc.
Fusion Pharmaceuticals Inc.
Genmab
Incyte Corporation
Seagen Inc.
Incyte Corporation
NKGen Biotech, Inc.
Daiichi Sankyo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)